Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (251-260 of 410) with videos related to

Pageof 41
Sort By:
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Cancer|July 20, 2024
Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trialMichael J Morris, Johann de Bono, James Nagarajah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancerMartin Smoragiewicz, Alice Bernard-Tessier, Mark Linch, et al.
The Journal of Urology|May 27, 2021
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN StudyNeeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
JAMA Oncology|May 6, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W Wyatt, Arun A Azad, Stanislav V Volik, et al.
The Journal of Pathology|July 18, 2018
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinomaEdmund Cp Chedgy, Gillian Vandekerkhove, Cameron Herberts, et al.
The Prostate|February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North AmericaAnthony M Joshua, Neal D Shore, Fred Saad, et al.
The Prostate|March 28, 2024
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancerKate L Mahon, Sarah Im Sutherland, Hui Ming Lin, et al.
Eclinicalmedicine|October 21, 2024
Multivariable models of outcomes with [<sup>177</sup>Lu]Lu-PSMA-617: analysis of the phase 3 VISION trialKen Herrmann, Andrei Gafita, Johann S de Bono, et al.
European Urology|March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate CancerKarim Fizazi, Kim N Chi, Johann S de Bono, et al.
Pageof 41

Showing results (251-260 of 410) with videos related to

Sort By:
Pageof 41
The Lancet. Oncology|March 12, 2017
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trialKim N Chi, Celestia S Higano, Brent Blumenstein, et al.
Cancer|July 20, 2024
Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trialMichael J Morris, Johann de Bono, James Nagarajah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 2, 2026
Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancerMartin Smoragiewicz, Alice Bernard-Tessier, Mark Linch, et al.
The Journal of Urology|May 27, 2021
Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN StudyNeeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
JAMA Oncology|May 6, 2016
Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate CancerAlexander W Wyatt, Arun A Azad, Stanislav V Volik, et al.
The Journal of Pathology|July 18, 2018
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinomaEdmund Cp Chedgy, Gillian Vandekerkhove, Cameron Herberts, et al.
The Prostate|February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North AmericaAnthony M Joshua, Neal D Shore, Fred Saad, et al.
The Prostate|March 28, 2024
Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancerKate L Mahon, Sarah Im Sutherland, Hui Ming Lin, et al.
Eclinicalmedicine|October 21, 2024
Multivariable models of outcomes with [<sup>177</sup>Lu]Lu-PSMA-617: analysis of the phase 3 VISION trialKen Herrmann, Andrei Gafita, Johann S de Bono, et al.
European Urology|March 12, 2016
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate CancerKarim Fizazi, Kim N Chi, Johann S de Bono, et al.
Pageof 41